Change of mentor to Mangold Fondkommission
Lumito AB has entered into an agreement with Mangold Fondkommission AB to act as the company's mentor in trading on NGM Nordic SME. Mangold Fondkommission will take over as mentor for the company on 15 October 2021. Lumito has simultaneously terminated the agreement with G&W Fondkommission AB, which expired on 14 October 2021. For further […]
Scanner with improved functionality installed
A life science consultant from TTP plc has delivered the next version of the Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2. – Due to the pandemic, this was […]
Patent application approved in an additional country – Brazil
Lumito's (https://lumito.se/en/home/) basic patent, a patent in the first patent family protecting the use of upconverting nanoparticles (UCNPs) for imaging in scattering materials, such as human tissue, has now been approved in Brazil. Among other countries, the company is awaiting response to an application concerning India. – The approval of our basic patent is an important […]
Lumito develops the tissue diagnostics of the future – basic patent now granted in Europe
Lumito's product comprises an instrument and staining reagents based on UCNPs (up-converting nanoparticles). The instrument is intended for use in tissue diagnostics, to provide pathologists visual depictions of tissue samples as an input for making diagnosis. The technology is patented across three global patent families that cover the creation of high-quality imaging of tissue, for […]
Patent approved also in India
The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada. – The grant of the […]
Processes in place for ISO 13485 qualification
Confirmation from an independent auditing company now shows that Lumito has the processes in place to qualify for ISO 13485. The first step has been passed and the next step in the process is for the company to demonstrate that the processes are being followed in practice. The processes reflect that the company is well […]
Lumito initiates process for listing on Nasdaq First North Growth Market
The Lund-based medical device company Lumito AB has initiated a process to list the Company's shares and warrants on Nasdaq First North Growth Market. As part of this process, a conditional application for delisting from NGM Nordic SME has been submitted to NGM. The application is conditional on Nasdaq’s approval of Lumito for listing on […]
The need for better diagnostic reliability is great and immediate, and Lumito has a solution with potential
These are the words of Björn Isfoss, Chief Pathologist and advisor to Lumito. The cooperation is fully in line with Lumito's strategy to build its own organization with the skills and capacity to manage and develop the current and future products. – I have chosen to work together with Lumito, whose technology has the capacity to meet […]
The instrument is to be delivered in June
Lumito's development partner TTP in Cambridge has informed that Lumito's instrument intended for validation in reference clinics is projected to be delivered in June, which is 6-8 weeks later than planned. The reason for the delay is the ongoing coronavirus pandemic and the fact that the UK has been in a state of lockdown for […]
Lumito appoints product specialist
Lumito develops instruments and staining reagents for digital pathology. The Lumito team is now joined by a new recruit. Tim Nilsson will take up appointment in the company on 9 March. “We are very pleased to have Tim Nilsson on board. He has a highly relevant background; he holds a Master of Science in chemistry […]